123 related articles for article (PubMed ID: 37988837)
1. Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma.
Capone E; Perrotti V; Cela I; Lattanzio R; Togni L; Rubini C; Caponio VCA; Lo Muzio L; Colasante M; Giansanti F; Ippoliti R; Iacobelli S; Wick MJ; Spardy Burr N; Sala G
Oral Oncol; 2024 Jan; 148():106635. PubMed ID: 37988837
[TBL] [Abstract][Full Text] [Related]
2. BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma.
Acasigua GA; Warner KA; Nör F; Helman J; Pearson AT; Fossati AC; Wang S; Nör JE
Oral Oncol; 2015 Sep; 51(9):839-47. PubMed ID: 26121939
[TBL] [Abstract][Full Text] [Related]
3. Establishment of PDX-derived salivary adenoid cystic carcinoma cell lines using organoid culture method.
Takada K; Aizawa Y; Sano D; Okuda R; Sekine K; Ueno Y; Yamanaka S; Aoyama J; Sato K; Kuwahara T; Hatano T; Takahashi H; Arai Y; Nishimura G; Taniguchi H; Oridate N
Int J Cancer; 2021 Jan; 148(1):193-202. PubMed ID: 32984947
[TBL] [Abstract][Full Text] [Related]
4. Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening.
Ling S; Rettig EM; Tan M; Chang X; Wang Z; Brait M; Bishop JA; Fertig EJ; Considine M; Wick MJ; Ha PK
Int J Oncol; 2016 Jul; 49(1):225-34. PubMed ID: 27212063
[TBL] [Abstract][Full Text] [Related]
5. LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma.
Cela I; Caponio VCA; Capone E; Pinti M; Mascitti M; Togni L; Lo Muzio L; Rubini C; De Laurenzi V; Lattanzio R; Perrotti V; Sala G
Oral Dis; 2024 May; 30(4):2039-2050. PubMed ID: 37649401
[TBL] [Abstract][Full Text] [Related]
6. A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug.
Chen C; Choudhury S; Wangsa D; Lescott CJ; Wilkins DJ; Sripadhan P; Liu X; Wangsa D; Ried T; Moskaluk C; Wick MJ; Glasgow E; Schlegel R; Agarwal S
Sci Rep; 2017 Sep; 7(1):11410. PubMed ID: 28900283
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
8. Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma.
Dufrusine B; Capone E; Ponziani S; Lattanzio R; Lanuti P; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Mangiola A; Trevisi G; Sala G
Mol Oncol; 2023 Aug; 17(8):1460-1473. PubMed ID: 37195369
[TBL] [Abstract][Full Text] [Related]
9. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
11. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
12. AKT3 drives adenoid cystic carcinoma development in salivary glands.
Zboray K; Mohrherr J; Stiedl P; Pranz K; Wandruszka L; Grabner B; Eferl R; Moriggl R; Stoiber D; Sakamoto K; Wagner KU; Popper H; Casanova E; Moll HP
Cancer Med; 2018 Feb; 7(2):445-453. PubMed ID: 29282901
[TBL] [Abstract][Full Text] [Related]
13. Expression of ERBB3 binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinicopathological relevance.
Sun J; Luo Y; Tian Z; Gu L; Xia SC; Yu Y
BMC Cancer; 2012 Oct; 12():499. PubMed ID: 23110497
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
17. In-depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type.
Bell D; Bell AH; Bondaruk J; Hanna EY; Weber RS
Cancer; 2016 May; 122(10):1513-22. PubMed ID: 26953815
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.
Nör F; Warner KA; Zhang Z; Acasigua GA; Pearson AT; Kerk SA; Helman JI; Sant'Ana Filho M; Wang S; Nör JE
Clin Cancer Res; 2017 Feb; 23(4):1036-1048. PubMed ID: 27550999
[No Abstract] [Full Text] [Related]
19. CXCR4 antagonist inhibits perineural invasion of adenoid cystic carcinoma.
Jeong WJ; Choi IJ; Park MW; An SY; Jeon EH; Paik JH; Sung MW; Ahn SH
J Clin Pathol; 2014 Nov; 67(11):992-8. PubMed ID: 25118295
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma.
Chu WF; Wu DM; Liu W; Wu LJ; Li DZ; Xu DY; Wang XF
Oral Oncol; 2009 Nov; 45(11):998-1004. PubMed ID: 19589718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
